Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lundbeck moves bipolar disorder candidate into phase II

Lundbeck moves bipolar disorder candidate into phase II

19th February 2008

Lundbeck has announced that it is to investigate Lu AA34893 as a treatment for bipolar disorder.

Following positive pre-clinical results and the conclusion of phase I trials in healthy individuals, the compound will now move into phase II of its clinical development.

The first patients have been enrolled in the study, which will assess the effects of Lu AA34893 on depressive episodes in bipolar disorder and investigate the potential of the compound in preventing the occurrence of mania.

Lundbeck reports that the mechanism of action for the compound encompasses a number of monoaminergic systems and includes allosteric effects that could prove beneficial in this field.

Anders Gersel Pedersen, senior vice-president and head of development at Lundbeck, said: “Lu AA34893 belongs to a new generation of psychotropics with a strong potential to show long-term effective mood stabilisation and thereby prevention of long-term disability in patients suffering from bipolar disorder.”

He added that the study marks the first entry of Lundbeck into the area of bipolar disorder and could provide a completely new approach to treating the disease.

Last month, Lundbeck announced the launch of phase I clinical studies of Lu AA37096 as a potential treatment for mood disorders.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.